Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily semaglutide for weight loss in obese subjects without diabetes
2014-001540-38Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in obesity (3 arms), sponsored by Novo Nordisk. Primary endpoint: Relative change from baseline in body weight (%). Started Jun 2015; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2014-001540-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001540-38.